REGENXBIO Inc. (RGNX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
REGENXBIO Inc. (RGNX) surged +2.35% to $7.41, trading at 18% of its 52-week range ($5.46 – $16.19). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 5, at 8:00 a.m. ET to discuss its financial results for the third quarter ended September 30, 2026, and operational
For questions about this article or underlying research, email help@trefis.com.
REGENXBIO (NASDAQ:RGNX) outlined its clinical, manufacturing and commercialization plans for sura-vec, an investigational one-time subretinal gene therapy for wet age-related macular degeneration, or wet AMD, during a co
REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases October 20, 2026 1:00 PM EDTCompany...
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +104.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RGNX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RGNX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, REGENXBIO Inc. (RGNX) ranks #669 by composite RQD confidence (39/100, grade D-) and #457 by equity capitalization ($489.2M). Within this direct 5-issuer industry benchmark cohort, RGNX leads on earnings valuation at N/A trailing P/E, while RGNX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VALN currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with RGNX at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RGNX
ACTIVE
REGENXBIO Inc. | D- | 39/100 | — | — | -35.0% | +2.35% | $489.2M | Benchmark Subject |
| SRZN Surrozen Inc. | E | 27/100 | — | — | -35.0% | -2.93% | $524.4M | /srzn-vs-rgnx → |
| EDIT Editas Medicine Inc. | D- | 37/100 | — | — | -35.0% | -0.68% | $450.0M | /edit-vs-rgnx → |
| PROK ProKidney Corp. (Class A) | D | 44/100 | — | — | -35.0% | -3.29% | $444.4M | /prok-vs-rgnx → |
| VALN Valneva SE | D+ | 58/100 | — | — | — | -0.52% | $541.8M | /valn-vs-rgnx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), REGENXBIO Inc. (RGNX) reported GAAP revenue of $170.4M (+104.5% vs. FY2024 revenue of $83.3M , and +88.9% cumulative change since FY2023) , GAAP net income of -$193.9M, operating cash flow of -$124.0M, and free cash flow of -$126.4M (+28.0% YoY). On the balance sheet, RGNX closed FY2025 with $453.0M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $170.4M | -$193.9M | -$124.0M | -$126.4M | $453.0M | — |
| FY2024 (FY) | 2024-12-31 | $83.3M | -$227.1M | -$173.1M | -$175.6M | $466.0M | — |
| FY2023 (FY) | 2023-12-31 | $90.2M | -$263.5M | -$218.4M | -$218.4M | — | — |
As of 2026-11-01, REGENXBIO Inc. (NASDAQ: RGNX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $7.41 (+2.35% 1D, market cap $489.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RGNX ranks #669 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), RGNX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SRZN (Surrozen Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $524.4M) and EDIT (Editas Medicine Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $450.0M). Among the 5-stock peer group, RGNX leads on earnings multiple (N/A) while RGNX leads on capital efficiency (-35.0% ROIC).
Per RGNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590877), REGENXBIO Inc. generated $170.4M in revenue (+104.5% YoY), -$193.9M in net income, and -$126.4M in free cash flow against $453.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RGNX last traded at $7.41 (+2.35% on volume of 1,035,633 shares), positioning the stock -7.14% below its 50-day simple moving average ($7.98) and -19.19% below its 200-day simple moving average ($9.17). Across its 52-week range of $5.46 to $16.19, RGNX sits at the 18.2% percentile with a 14-day RSI of 46.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.48 to $8.34).
Why RGNX Stock surged +2.35% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.